Identification
- Summary
-
Mephenesinis a cresol glyceryl ether used to treat muscle spasticity in Parkinson's and Multiple Sclerosis.
- Generic Name
- Mephenesin
- DrugBank Accession Number
- DB13583
- Background
-
Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression1. It first entered use in the 1950s.
- Type
- Small Molecule
- Groups
- Approved
- Structure
-
Structure for Mephenesin (DB13583)
- Weight
-
Average: 182.219
Monoisotopic: 182.094294311 - Chemical Formula
- C10H14O3
- Synonyms
-
- Mephenesin
Pharmacology
- Indication
-
Mephenesin was used for the treatment of muscle spasticity in diseases like Parkinson's or Multiple Sclerosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Mephenesin reduced neuronal excitability leading to decreases action potentials to muscle fibers which ultimately produces a reduction in spasticity2.
- Mechanism of action
-
The exact mechanism of action of mephenesin is not known. It has been observed to block both inward sodium and inward calcium currents in neurons3. It has a physiological effect which opposes that of strychnine.
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Mephenesin can produce hemolysis leading to hemoglobinuria with intravenous administration of concentrations greater than 10%1. As a central nervous system depressant it can also produce paralysis and respiratory depression.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBaclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Mephenesin. Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Mephenesin. Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mephenesin. Daridorexant The risk or severity of CNS depression can be increased when Mephenesin is combined with Daridorexant. Fluoxetine Mephenesin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. Haloperidol The risk or severity of CNS depression can be increased when Haloperidol is combined with Mephenesin. Lasmiditan The risk or severity of adverse effects can be increased when Lasmiditan is combined with Mephenesin. Metoclopramide The risk or severity of sedation can be increased when Metoclopramide is combined with Mephenesin. Midazolam The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Mephenesin. Oliceridine The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Mephenesin is combined with Oliceridine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Mixture Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Decontractyl Baume Mephenesin(10 %)+Methyl nicotinate(1 %) Ointment Topical Robert and Carriere Lab 1962-12-31 1998-07-22 Canada 
Categories
- ATC Codes
- M03BX06 — Mephenesin
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Not Available
- Direct Parent
- Phenol ethers
- Alternative Parents
- Phenoxy compounds/Toluenes/Alkyl aryl ethers/二级醇/1,2-diols/Primary alcohols/Hydrocarbon derivatives
- Substituents
- 1,2-diol/Alcohol/Alkyl aryl ether/Aromatic homomonocyclic compound/Ether/Hydrocarbon derivative/Monocyclic benzene moiety/有机含氧的gen compound/Organooxygen compound/Phenol ether
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7B8PIR2954
- CAS number
- 59-47-2
- InChI Key
- JWDYCNIAQWPBHD-UHFFFAOYSA-N
- InChI
-
InChI=1S/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3
- IUPAC Name
-
3-(2-methylphenoxy)propane-1,2-diol
- SMILES
-
CC1=CC=CC=C1OCC(O)CO
References
- 一般References
-
- Authors unspecified: NEW and nonofficial remedies; mephenesin. J Am Med Assoc. 1950 Jun 17;143(7):655. [Article]
- KAADA BR: Site of action of myanesin in the central nervous system. J Neurophysiol. 1950 Jan;13(1):89-104. doi: 10.1152/jn.1950.13.1.89. [Article]
- Klee MR, Faber DS: Mephenesin blocks early inward currents and strychnine-induced multiple discharges of aplysia neurons. Pflugers Arch. 1974 Feb 4;346(2):97-106. [Article]
- External Links
-
- ChemSpider
- 3919
- BindingDB
- 50238673
- 6755
- ChEBI
- 94398
- ChEMBL
- CHEMBL229128
- Wikipedia
- Mephenesin
- MSDS
-
Download (47 KB)
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Ointment Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
-
Property Value Source melting point (°C) 71 MSDS water solubility Sparingly soluble NEW and nonofficial remedies; mephenesin. J Am Med Assoc. 1950;143(7):655. - Predicted Properties
-
Property Value Source 水溶度 20.8 mg/mL ALOGPS logP 0.96 ALOGPS logP 1.01 Chemaxon logS -0.94 ALOGPS pKa (Strongest Acidic) 13.62 Chemaxon pKa最强(基本) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 49.69 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 49.82 m3·mol-1 Chemaxon Polarizability 19.7 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key GC-MS Spectrum - EI-B GC-MS splash10-0a4i-5900000000-3ce39ed63d61e07d52b5 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:44 / Updated at February 21, 2021 18:54